Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence

Thromb Haemost. 1994 Mar;71(3):280-3.

Abstract

An extensive comparison has been performed on the clinical chemistry automate Hitachi 717 between thrombin- and Factor Xa-based methods for determination of antithrombin III activity. In 460 patients who did not receive any heparin therapy the agreement between assays was in general close although the thrombin-based methods resulted in slightly higher assignments of 0.3-2.6% antithrombin III activity. The discrepancy was, however, substantial in plasmas from patients receiving heparin of > or = 20000 IU/day, resulting in plasma levels of heparin of 0.8-1.2 IU/ml. Thus, analysis of 102 patients showed that the thrombin-based methods resulted in, on average, 7-16% higher assignment of antithrombin III activity as compared to the Factor Xa-based method used. Addition of antibodies to antithrombin III and heparin cofactor II revealed that the discrepancy was primarily due to contribution of heparin cofactor II activity in the thrombin-based methods. The results thus suggest that the Factor Xa-based antithrombin III activity method provides more valid results in patients on heparin therapy.

Publication types

  • Comparative Study

MeSH terms

  • Antithrombin III / analysis*
  • Artifacts*
  • Blood Coagulation Tests*
  • Factor Xa Inhibitors
  • Heparin / therapeutic use*
  • Heparin Cofactor II / pharmacology*
  • Humans
  • Thrombin / antagonists & inhibitors*

Substances

  • Factor Xa Inhibitors
  • Heparin Cofactor II
  • Antithrombin III
  • Heparin
  • Thrombin